“In the field of prostate cancer treatment, researchers have identified ADP-dependent glucokinase (ADPGK) as a crucial target. The study found that high ADPGK expression is associated with poor survival outcomes in prostate cancer patients. ADPGK accelerates cancer glycolysis and progression by activating the ALDOC-AMPK signaling pathway, laying a foundation for the construction of a new treatment and prognosis evaluation system for prostate cancer.”